Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05397132 · ClinicalTrials.gov registry record
Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies
A clinical trial of Hematologic Malignancy, sponsored by Duke University.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05397132: Recruiting study of Hematologic Malignancy, sponsored by Duke University.
NCT05397132 is a study of Hematologic Malignancy that is actively recruiting participants, run by Duke University. The registered enrollment target is 50 participants, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05397132, a study of Hematologic Malignancy, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.
Primary Outcome
multivariable regression
Conditions Studied
Interventions
- GENETIC Blood draw
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-11-01 |
What NCT05397132 shows while recruiting
NCT05397132 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT05397132 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05397132 about?
NCT05397132 is a clinical study titled "Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies". The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistanc...
What is the current status of trial NCT05397132?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-05-27. Estimated completion is 2026-11-01.
What conditions does trial NCT05397132 study?
This clinical trial studies the following conditions: Hematologic Malignancy.
What interventions are being tested in trial NCT05397132?
The interventions under investigation include: Blood draw (GENETIC).
Who is sponsoring clinical trial NCT05397132?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05397132 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05397132's enrollment target sits among peer trials
50 28th of 48 higher than 19 of 48 other Hematologic Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
RECRUITING
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI